*sigh* let's not set ourselves up for another disappointment. It's good news that the DSMC recommends another interim analysis. There's no guarantee that the recommendation then will be to request EUA. But there's a higher likelihood than there was with the first interim analysis.

Why is there SO MUCH caution with an almost commercialized drug (for HIV) when there is so much death and suffering? It's very frustrating.